Menu

The facts on Hydrazine

Table of contents

The facts on Hydrazine

Last update April 11, 2024

In the EU, about 2.1 million workers are estimated to be potentially exposed to hydrazine. The primary routes of potential human exposure to hydrazine are inhalation, ingestion, and dermal contact. Hydrazine is classified as category 1B carcinogen according to CLP regulation, meaning that the substance may cause cancer in humans. It may increase the risk of lung, colorectal, nasal and liver cancer.

Where risks occur

Hydrazine is used in the manufacture of pharmaceuticals, agrochemicals, as a chemical blowing agent, in paints, inks and organic dyes, polyurethane coatings, and adhesives. In addition, hydrazine has several direct applications as an oxygen scavenger, a corrosion inhibitor, a reducing agent, and a propellant. Exposure predominantly occurs in the workplace and has been documented in the paper, tire-manufacturing, military, and aerospace industries where hydrazine is either produced or handled for example as a rocket propellant and in the refilling of fighter aircrafts.

More about the substance

Hydrazine is a colorless oily liquid at room temperature with a penetrating ammonia-like odor. Its liquid and vapour are flammable. It is miscible with methyl, ethyl, propyl, and butyl alcohols, slightly miscible with hydrocarbons and halogenated hydrocarbons, and insoluble in chloroform and ether. It is used primarily as a chemical intermediate to produce agricultural chemicals (e.g., pesticides) and chemical blowing agents, polymer additives, polymers, dyes and active pharmaceutical ingredients. Application is known as a corrosion inhibitor, as a flux for soldering, as water-treatment chemical, and as rocket and satellite propellant.

How symptoms can affect you

Hydrazine is known to be toxic by skin contact, inhalation and ingestion. The symptoms of acute (short-term) exposure to high levels of hydrazine may include irritation of the eyes, nose, and throat, dizziness, headache, nausea, pulmonary edema, seizures, and coma in humans. Acute exposure can also damage the liver, kidneys, and central nervous system in humans. The liquid is corrosive to skin and eyes and may produce dermatitis from skin contact.

Prolonged exposure may cause lung, colorectal, nasal and liver cancer.

What you can do

Perform proper exposure measurements continuously so it is known when actions should be taken. Investigate if workers report early symptoms. Workers need to be aware of the effects of exposure. Substitution is possible for certain uses, e.g. as corrosion protection and oxygen binding agent in hot water/steam systems or as fluxes. Different formulations as substitute are on the market. The control measures include enclosed processes. Specific dose pumping systems can help to avoid direct exposure. Further, local exhaust and general ventilation are common measures in place. After these technical solutions have been exhausted, subsequent work practices to be introduced are providing employees with hazard information and training, providing eye wash fountains and emergency showers, washing body parts at the end of the workshift and prohibit eating, smoking or drinking in chemical handling areas. Personal protective equipment should consist of a mask, glasses, impermeable gloves and clothing. Personal protective equipment (PPE) should only be used as a last resort, after introducing the possible engineering solutions. It has been reported that good practice and the use of appropriate PPE are common measures in the agriculture industry.

Sources: BAuA, CLP, ECHA, IARC, KOM, SCOEL, US EPA

Limit values

EU
0,013 mg/m³
 Austria
0,013 mg/m³ (TWA)
0,052 mg/m³ short ter
 Belgium
0.013 mg/m3 (TWA)
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
0,013 mg/m³ (TWA)
0,026 mg/m³ short term
Estonia
EU directive
Finland
0,013 mg/m³ (TWA)
0,07 mg/m³ short term
France
0,013 mg/m³
Germany
0,022 mg/m³ (TWA)
0,044 mg/m³ short term
Greece
EU directive
Hungary
0,13 mg/m³
Iceland
EU directive
Ireland
0,013 mg/m³
Italy
0,013 mg/m³
Latvia
0,013 mg/m³
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
8h-TWA: 0.013 mg/m3 (0.01 ppm)
North Macedonia
0,13 mg/m³ (TWA)
0,52 mg/m³ short term
Norway
0,01 mg/m³ (TWA)
Poland
0,013 mg/m³
Portugal
EU directive
Romania
0,013 mg/m³
Serbia
EU directive
Slovakia
EU directive
Slovania
EU directive
Spain
VLA-ED= 0,1 ppm (0,013 mg/m3)
Sweden
0,013 mg/m³
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

Possible substitutions

Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
ECHA registration
CAS number 302-01-2
EC number 206-114-9
Annex VI of CLP 1B
Number of registrations (2023) 12
Tonnage band registred (2023) 10.000 to < 100.000

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Every year, almost 100.000 people die from cancer that was caused by exposure at work
  • Annually more than 100.000 people die because of work-related cancer.
Table of contents